On August 13th, the reporter learned from AstraZeneca that the company has jointly developed and commercialized the Youhede& reg; (Common name: Dexmedetomidine for injection) has recently received conditional approval from the China National Medical Products Administration. This product is suitable as a monotherapy for the treatment of locally advanced or metastatic HER2 positive adult gastric or gastroesophageal junction adenocarcinoma patients who have previously received two or more treatment regimens.
Dequtuzumab is a uniquely designed antibody conjugated drug (ADC) targeting HER2, jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. On February 21, 2023, Detriazumab was officially approved by the State Food and Drug Administration for marketing, and since then, it has been successively approved for single drug treatment for unresectable or metastatic HER2 positive adult breast cancer patients who have previously received one or more anti HER2 drugs; Or those who have received at least one systematic treatment in the past at the stage of metastatic disease, or who recur during adjuvant chemotherapy or within 6 months after completing adjuvant chemotherapy, adult breast cancer patients with unresectable or metastatic HER2 low expression (IHC 1+or IHC 2+/ISH -).
AstraZeneca stated that this therapy has been approved for its third indication in China, bringing new treatment options for HER2 positive advanced gastric cancer patients in the country.